Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less..... -- Ignore unavailable to you. Want to Upgrade?

To: Findit who wrote (58710)	5/24/2007 11:44:04 AM
From: Findit	Read Replies (3) \| Respond to of 59879

CLN holding gains. Now 5.65 +.70. They have plenty of cash and Boston Scientific has a large position in the company. Here a snip of a report on early findings of their cancer drug - COLUMBIA, Md.--(BUSINESS WIRE)--CELSION CORPORATION (AMEX:CLN - News) today reported that on May 16, 2007 at the joint meeting of the World Congress on Interventional Oncology and the Society for Thermal Medicine, in Washington DC, Dr. Zeljko Vujaskovic, Associate Clinical Professor at Duke University, presented early data from a Phase I dose escalation and safety study using ThermoDox to treat patients with recurrent breast cancer on the chest wall. He reported that at low doses (three patients at 20mg/m2 and three patients at 30mg/m2), after only two cycles of a six cycle regimen, all six patients showed early signs of clinically meaningful activity, one patient had a complete response in the treated area, two patients had a partial response and three patients had stable disease following treatment.